Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), Giulio Metro(University of Perugia), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Giuliana D’Auria(Ospedale di Belcolle), Michelangelo Russillo(National Cancer Institute), Paola Papaldo(Cancer Institute (WIA)), Ferdinando De Vita(University of Campania "Luigi Vanvitelli"), Diana Giannarelli(Agostino Gemelli University Polyclinic), Antonello Vidiri
Cited by 22
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|347